652 related articles for article (PubMed ID: 15591457)
21. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
[TBL] [Abstract][Full Text] [Related]
22. Expression of thymidylate synthase in relation to survival and chemosensitivity in gastric cancer patients.
Tsujitani S; Konishi I; Suzuki K; Oka S; Gomyo Y; Matsumoto S; Hirooka Y; Kaibara N
J Exp Clin Cancer Res; 2000 Jun; 19(2):189-95. PubMed ID: 10965817
[TBL] [Abstract][Full Text] [Related]
23. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.
Ichikawa W; Uetake H; Shirota Y; Yamada H; Nishi N; Nihei Z; Sugihara K; Hirayama R
Clin Cancer Res; 2003 Feb; 9(2):786-91. PubMed ID: 12576451
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical dihydropyrimidine dehydrogenase expression is a good prognostic indicator for patients with Dukes' C colorectal cancer.
Oi K; Makino M; Ozaki M; Takemoto H; Yamane N; Nakamura S; Ikeguchi M; Kaibara N
Anticancer Res; 2004; 24(1):273-9. PubMed ID: 15015608
[TBL] [Abstract][Full Text] [Related]
25. [Hepatic recurrence after prophylactic hepatic arterial infusion of 5-fluorouracil for Dukes' C colorectal cancer--correlation with the expression of dihydropyrimidine dehydrogenase in the primary tumor].
Ishida H; Takeuchi I; Ohsawa T; Nakada H; Ishizuka N; Yokoyama M; Inokuma S; Suzuki T; Yamada H; Odaka A; Hoshino T; Murata N; Hashimoto D; Matsumoto Y; Miura T
Gan To Kagaku Ryoho; 2002 Nov; 29(12):2267-70. PubMed ID: 12484051
[TBL] [Abstract][Full Text] [Related]
26. dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer.
Ladner RD; Lynch FJ; Groshen S; Xiong YP; Sherrod A; Caradonna SJ; Stoehlmacher J; Lenz HJ
Cancer Res; 2000 Jul; 60(13):3493-503. PubMed ID: 10910061
[TBL] [Abstract][Full Text] [Related]
27. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer.
Johnston PG; Fisher ER; Rockette HE; Fisher B; Wolmark N; Drake JC; Chabner BA; Allegra CJ
J Clin Oncol; 1994 Dec; 12(12):2640-7. PubMed ID: 7989939
[TBL] [Abstract][Full Text] [Related]
28. Thymidylate synthase and p53 expression in primary tumor do not predict chemotherapy outcome in metastatic colorectal carcinoma.
Berglund A; Edler D; Molin D; Nordlinder H; Graf W; Glimelius B
Anticancer Res; 2002; 22(6B):3653-9. PubMed ID: 12552972
[TBL] [Abstract][Full Text] [Related]
29. Recurrence and 5-FU sensitivity of stage III/Dukes' C colorectal cancer with occult neoplastic cells in lymph node sinuses.
Mukai M; Sato S; Ninomiya H; Wakui K; Komatsu N; Tsuchiya K; Nakasaki H; Makuuchi H
Oncol Rep; 2005 Nov; 14(5):1165-9. PubMed ID: 16211280
[TBL] [Abstract][Full Text] [Related]
30. Cell cycle regulation of the G0/G1 transition in 5-fluorouracil-sensitive and -resistant human colon cancer cell lines.
McGinn CJ; Pestalozzi BC; Drake JC; Glennon MC; Kunugi K; Otterson G; Allegra CJ; Johnston PG; Kinsella TJ
Cancer J; 2000; 6(4):234-42. PubMed ID: 11038143
[TBL] [Abstract][Full Text] [Related]
31. Thymidylate synthase expression pattern is a prognostic factor in patients of colorectal cancer treated with 5-fluorouracil.
Fernández-Contreras ME; Jiménez De Ayala B; García De Paredes ML; Velasco A; Majano PL; Palacios J; Gamallo C
Int J Oncol; 2004 Oct; 25(4):877-85. PubMed ID: 15375535
[TBL] [Abstract][Full Text] [Related]
32. Do the expression of CD44, apoptosis and thymidylate synthase inhibition rate correlate with the efficacy of chemotherapy in colorectal cancer?
Tachikawa D; Arima S; Futami K; Iwashita A
Anticancer Res; 2000; 20(1C):595-600. PubMed ID: 10769701
[TBL] [Abstract][Full Text] [Related]
33. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy.
Edler D; Glimelius B; Hallström M; Jakobsen A; Johnston PG; Magnusson I; Ragnhammar P; Blomgren H
J Clin Oncol; 2002 Apr; 20(7):1721-8. PubMed ID: 11919227
[TBL] [Abstract][Full Text] [Related]
34. Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients.
Paradiso A; Simone G; Petroni S; Leone B; Vallejo C; Lacava J; Romero A; Machiavelli M; De Lena M; Allegra CJ; Johnston PG
Br J Cancer; 2000 Feb; 82(3):560-7. PubMed ID: 10682666
[TBL] [Abstract][Full Text] [Related]
35. Recurrence and 5-FU sensitivity of stage II/Dukes' B colorectal cancer with occult neoplastic cells in lymph node sinuses.
Mukai M; Sato S; Ninomiya H; Wakui K; Komatsu N; Tsuchiya K; Nakasaki H; Makuuchi H
Oncol Rep; 2005 Nov; 14(5):1171-6. PubMed ID: 16211281
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant therapy of colorectal cancer.
Kemeny N; Saltz L; Cohen A
Surg Oncol Clin N Am; 1997 Oct; 6(4):699-722. PubMed ID: 9309089
[TBL] [Abstract][Full Text] [Related]
37. An anticancer drug sensitivity test to determine the effectiveness of UFT as postoperative adjuvant chemotherapy for patients with stage III colorectal cancer.
Isogai A; Nagaya M; Matsuoka H; Watanabe T; Tsukikawa S; Kubota S
Surgery; 2007 Nov; 142(5):741-8. PubMed ID: 17981195
[TBL] [Abstract][Full Text] [Related]
38. [Expression of mRNA levels of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase of colorectal cancer--relationships among mRNA levels in association with response to 5-FU based treatment].
Ishida H; Shirakawa K; Ohsawa T; Sobajima J; Hayashi Y; Nakada H; Yokoyama M; Hashimoto D
Gan To Kagaku Ryoho; 2005 Nov; 32(12):1929-34. PubMed ID: 16282729
[TBL] [Abstract][Full Text] [Related]
39. Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group.
Dahl O; Fluge Ø; Carlsen E; Wiig JN; Myrvold HE; Vonen B; Podhorny N; Bjerkeset O; Eide TJ; Halvorsen TB; Tveit KM;
Acta Oncol; 2009; 48(3):368-76. PubMed ID: 19242829
[TBL] [Abstract][Full Text] [Related]
40. Indication and efficacy of adjuvant chemotherapy with oral fluoropyrimidines for dukes' B colorectal cancer.
Yoshimatsu K; Umehara A; Ishibashi K; Yokomizo H; Yoshida K; Fujimoto T; Watanabe K; Ogawa K
Anticancer Res; 2006; 26(4B):3089-93. PubMed ID: 16886639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
